Gilead & Janssen v. Lupin & MSN: Genvoya Generic Blocked by Consent Judgment
Gilead Sciences and Janssen filed suit in Delaware in November 2021 against Lupin and MSN entities challenging ANDA No. 218575 — a proposed generic for a four-drug HIV combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. After 1,190 days, the parties resolved the dispute via consent judgment, with defendants permanently enjoined from U.S. commercialisation of the ANDA product.
HIV Combination Therapy Patents Enforced via Agreed Injunction in Delaware
Gilead Sciences, Inc., together with co-plaintiffs Janssen Sciences Ireland Unlimited Company, Gilead Sciences Ireland UC, and Janssen Products LP, filed this Hatch-Waxman patent infringement action on 16 November 2021 in the U.S. District Court for Delaware before Judge Maryellen Noreika. The defendants — Lupin Limited, Lupin Pharmaceuticals Inc., MSN Pharmaceuticals Inc., MSN Life Sciences Private Ltd., and MSN Laboratories Private Ltd. — had filed ANDA No. 218575 seeking FDA approval for a generic version of the four-drug HIV antiviral combination of elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg), referencing Gilead’s branded Genvoya product. Four patents were asserted: US10039718B2, US8497396B2, US9428473B2, and US10786518B2.
The case closed on 18 February 2025 through a consent judgment — a negotiated court order signed by both parties and entered by the court without a full trial. Under the order, all affirmative defenses, claims, and counterclaims were dismissed without prejudice, preserving defendants’ theoretical future ability to relitigate if circumstances change. Critically, the defendants and their affiliates were permanently enjoined from making, using, selling, offering for sale, or importing the ANDA No. 218575 product in the United States, unless authorised by Gilead or permitted under 35 U.S.C. § 271(e)(1). The FDA retains authority to grant final approval to Apotex’s ANDA, consistent with standard Hatch-Waxman practice.
The 1,190-day duration — over three years — is consistent with the typical lifecycle of a contested ANDA litigation in Delaware, where cases often proceed through claim construction and expert discovery before settlement. The consent judgment with injunction, rather than a simple voluntary dismissal, suggests the brand-name plaintiffs obtained meaningful protection: defendants are bound by a court order, not merely a private agreement. The public record does not disclose any licensing terms, authorised generic arrangements, or market entry dates, which are commonly negotiated confidentially in parallel to the court filing.
Filing to Consent Judgment in 1190 days
1,190 days — over 3 years from filing to consent judgment, longer than median ANDA patent cases
Consent judgment with injunction: what the order means for each party
Consent judgment is a court order, not just a settlement
A consent judgment differs from a simple voluntary dismissal: it is entered by the court and carries the full force of a judicial order. Here, all claims were dismissed without prejudice — meaning no merits ruling was made — but the accompanying permanent injunction is independently enforceable. Defendants who violate it face contempt of court, not merely breach of contract.
Court-enforceable injunctionClaims dismissed without prejudice preserves future options
Dismissal without prejudice means neither party received a merits adjudication on validity, infringement, or enforceability of the four asserted patents. Defendants could theoretically refile or raise the same defenses if circumstances change — for example, if a post-grant proceeding invalidates a patent. However, the injunction on the specific ANDA product substantially limits practical re-entry absent a licensing arrangement or successful patent challenge.
No merits ruling on patentsGilead and Janssen secure enforceable market exclusivity
The consent judgment gives Gilead and Janssen a court-ordered injunction blocking Lupin and MSN from commercialising the ANDA product in the U.S. without authorisation. This protects Genvoya-related revenues without the cost and risk of full trial. Each party bearing its own costs suggests a balanced negotiation, with the brand holders accepting no fee recovery in exchange for a clean injunction.
Injunction secured, no royalty disclosedGeneric entry on this ANDA blocked pending authorisation or patent expiry
With the injunction in place, Lupin and MSN cannot launch the four-drug HIV combination product in the U.S. under ANDA No. 218575 without Gilead’s authorisation. The FDA retains approval authority, so an authorised generic or future licensing deal remains possible. Competitors in the HIV combination therapy space should note the enforceability of the four asserted patents has not been adjudicated, leaving room for IPR or other post-grant challenges.
Market entry blocked; IPR remains viableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Gilead Sciences, Inc. | Company | Pharmaceutical innovators and HIV therapy IP holders — asserting US10039718B2 and three further patentsSearch in Eureka ↗ |
| Co-Plaintiff | Janssen Sciences Ireland Unlimited Company | Company | Search in Eureka ↗ |
| Co-Plaintiff | Gilead Sciences Ireland, UC | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Janssen Products, LP | Company | Search in Eureka ↗ |
| Defendant | Lupin Limited | Individual | Generic pharmaceutical manufacturers Lupin and MSN seeking FDA approval for Genvoya-referencing ANDASearch in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Life Sciences Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charlotte C. Jacobsen | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jon T. Tanaka | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew E. Morrell | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Aryeh N. Feinstein | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Jared C. Bunker | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Jeremiah S. Helm | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Jonathan E. Bachand | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Kenneth O. Aruda | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Matthew S. Friedrichs | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | William R. Zimmerman | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is carefully structured to deliver enforceable market protection without a merits adjudication. The dismissal without prejudice of all claims and counterclaims is standard in negotiated ANDA resolutions — it avoids binding precedent on patent validity while the permanent injunction on ANDA No. 218575 provides Gilead and Janssen with the practical equivalent of a plaintiff win. The explicit retention of court jurisdiction for enforcement, combined with the parties’ waiver of appeal rights, makes this order self-contained and immediately operative. The clause preserving FDA approval authority is a routine Hatch-Waxman formality and does not signal any authorised generic arrangement from the public record.
US10039718B2 — HIV four-drug combination antiviral therapy
US10039718B2, filed under application number US12/434513, protects a pharmaceutical combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide — the active ingredients in Gilead’s Genvoya, a once-daily single-tablet regimen for HIV-1 infection. The three co-asserted patents (US8497396B2, US9428473B2, US10786518B2) cover related aspects of the TAF-based combination chemistry and formulation, spanning application families from the early 2010s through to a 2018 filing date for the most recent. Together, the portfolio reflects layered protection across compound, formulation, and method-of-use claims.
Genvoya’s commercial significance — as one of the leading single-tablet HIV regimens globally — makes this patent portfolio a high-value enforcement asset. The four-drug combination integrating tenofovir alafenamide (TAF) over its predecessor tenofovir disoproxil fumarate (TDF) was a clinically meaningful advance, with improved renal and bone safety profiles supporting premium pricing. Any generic entrant seeking to market a TAF-containing HIV combination in the U.S. must clear this portfolio. The consent judgment in this case suggests at least these defendants assessed the litigation risk unfavourably, though no validity findings were made.
Should you run an FTO against US10039718B2 and the Genvoya patent portfolio?
Any pharmaceutical company developing, filing an ANDA for, or commercialising a four-drug HIV combination containing tenofovir alafenamide in the U.S. should treat this patent family as a primary FTO priority. The consent judgment in this case demonstrates that Gilead and Janssen will enforce these patents aggressively at the district court level, and the absence of a merits ruling means no prior art or invalidity findings are available to rely upon from this litigation.
PatSnap Eureka’s FTO Search Agent can map the full citation landscape around US10039718B2 and its co-asserted patents, identify expiry dates across the US8497396, US9428473, and US10786518 families, and surface any post-grant proceedings that may affect enforceability. For R&D and regulatory teams assessing ANDA filing timelines for TAF-based HIV combinations, Eureka provides claim-level analysis and prior art mapping to support freedom-to-operate opinions before submission.
Run a freedom-to-operate analysis on US10039718B2 to assess your product’s exposure
Run FTO in Eureka →Related HIV antiviral ANDA patent cases in Delaware and comparable jurisdictions
Compare this Delaware ANDA case with other HIV combination therapy patent disputes involving TAF, elvitegravir, and cobicistat formulations.
What this case signals for the HIV antiviral IP landscape
Consent judgments with injunctions in ANDA cases signal patent holder confidence — and create durable market exclusivity without litigation risk.
Consent judgments with injunctions are the preferred ANDA endgame for brand holders
Rather than pursuing a full bench trial, Gilead and Janssen secured a court-enforceable injunction through consent. This approach avoids the validity risk of a trial verdict while delivering stronger protection than a private settlement alone. IP teams defending innovation in HIV combination therapy should treat consent judgment templates as a standard strategic tool.
Four patents asserted — no merits ruling leaves the portfolio untested
With dismissal without prejudice and no court ruling on validity or infringement of US10039718B2, US8497396B2, US9428473B2, or US10786518B2, the strength of these patents remains unlitigated. Generic challengers considering IPR petitions against this portfolio face no estoppel from this case — the public record is silent on claim scope.
Gilead v Lupin — key questions answered
The case closed on 18 February 2025 via a consent judgment. All claims were dismissed without prejudice and the defendants — Lupin and MSN entities — were permanently enjoined from making, selling, or importing the ANDA No. 218575 product in the U.S. without Gilead’s authorisation. No merits ruling on patent validity or infringement was made.
Four patents were asserted: US10039718B2, US8497396B2, US9428473B2, and US10786518B2. These cover various aspects of the four-drug HIV combination therapy containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide — the active ingredients in Gilead’s Genvoya single-tablet regimen.
Dismissed without prejudice means no court ruling was made on the merits of the patent infringement, validity, or enforceability claims. The defendants theoretically retain the right to raise those same defenses in future proceedings — for example, via an IPR petition challenging the asserted patents. However, the permanent injunction on the specific ANDA product remains fully enforceable regardless.
Not without authorisation from Gilead. The consent judgment permanently enjoins Lupin, MSN, and their affiliates from commercialising ANDA No. 218575 in the U.S. unless authorised by Gilead or permitted under the Hatch-Waxman safe harbour (35 U.S.C. § 271(e)(1)). The FDA may still grant approval, but commercial launch without authorisation would constitute contempt of court.
ANDA No. 218575 is the Abbreviated New Drug Application filed by Apotex/MSN entities for a generic version of Genvoya — Gilead’s branded single-tablet HIV-1 regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg. The ANDA filing triggered Gilead and Janssen’s patent infringement suit under the Hatch-Waxman framework.
PatSnap Eureka searches patents and litigation data to answer instantly.